Revolutionising the treatment of eczema with novel peptide technology

Carocell Bio is more than just a name - it’s an evolution in skincare

We are at the forefront of a peptide-based, anti-inflammatory approach to heal and promote healthier skin and help treat skin-related conditions

Treatment of Eczema (Atopic Dermatitis)

Eczema (atopic dermatitis) is the most common skin disease, and is often a chronic condition

Current treatments carry significant safety risks

Our lead peptide, JEL3108, works in biopsies from patients with eczema

Our novel peptide technology will safely revolutionise the management of eczema

Prevention - stops eczema coming back

Our patented peptide can not only treat eczema – if its use is continued, it will be able to prevent the disease coming back

Giving you healthier, happier skin over the longer-term

Delay skin ageing

A significant component of skin ageing is related to inflammation

Our treatment, which is developed for topical application to the skin, has the potential to be used as an anti-ageing treatment

Carocell Bio would be more than happy to discuss any of these indications

Our Research and Data.

We have proprietary peptide-based anti-inflammation technology, with highly potent and highly selective therapeutic peptides that inhibit intracellular mitogen-activated protein kinase (MAPK, p38).

Our portfolio of novel molecules inhibit the inflammatory cascade, combining them with a nanoparticle delivery technology that can be applied to the skin.

Our Leadership Team

Carocell Bio’s leadership team has extensive global experience in drug development – from idea through to market

Dr Mike Davies MD, FRCS

CEO & Founder

  • Edinburgh University
  • Fully-trained surgeon
  • More than 25 years’ experience in drug development
  • Invested >$650,000 into Carocell Bio
John Nicholson

John Nicholson, PhD


  • University of Cambridge
  • International pharma experience: Start-up to market
  • Highly networked with pharma
  • Raised new capital for several startups
  • Chair and CEO of Gentronix to 2019
david browning

David Browning

Strategic Advisor

  • 40 years life-science experience translating scientific discoveries to deliver global market impact. 

  • NHS biochemist, Amersham international, J&J, Philips, Oxford and other University spin-outs, MediCity/ BioCity, multiple advisory and Board roles

Professor Ashley George

Prof. Ashley George CC FRSC

Financial Director

  • Capital raised from startup to IPO companies on NYSE
  • Access to investment

Scientific and Clinical Advisors

Professor Anne Dickinson, PhD

Emerita Professor, Newcastle University and Director of Newcastle Cellular Therapies Facility

Professor Anthony Sedgwick, PhD

Honorary Professor, Swansea University Medical School; Non-Executive Director, Emergex Vaccines

Professor Yvonne Perrie, PhD

Drug Delivery, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow